These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 29866366)

  • 21. Certolizumab pegol for the treatment of psoriasis.
    Campanati A; Benfaremo D; Luchetti MM; Ganzetti G; Gabrielli A; Offidani A
    Expert Opin Biol Ther; 2017 Mar; 17(3):387-394. PubMed ID: 28165828
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alefacept in the treatment of psoriatic nail disease: a proof of concept study.
    Parrish CA; Sobera JO; Robbins CM; Cantrell WC; Desmond RA; Elewski BE
    J Drugs Dermatol; 2006 Apr; 5(4):339-40. PubMed ID: 16673801
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Extended report: nail disease in psoriatic arthritis--clinically important, potentially treatable and often overlooked.
    Williamson L; Dalbeth N; Dockerty JL; Gee BC; Weatherall R; Wordsworth BP
    Rheumatology (Oxford); 2004 Jun; 43(6):790-4. PubMed ID: 15113998
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Successful Use of Certolizumab Pegol for Refractory Psoriatic Arthritis Triggered by COVID-19 Infection.
    Ohmura SI; Homma Y; Hanai S; Miyamoto T
    Intern Med; 2022 Feb; 61(3):433-438. PubMed ID: 34803106
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term treatment of psoriatic patients with adalimumab reduces disease severity and maintains a favorable lipid pattern and a low Atherogenic Index.
    Zangrilli A; Bavetta M; Scaramella M; Bianchi L
    G Ital Dermatol Venereol; 2018 Apr; 153(2):146-154. PubMed ID: 29564871
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study.
    Smolen JS; Burmester GR; Combe B; Curtis JR; Hall S; Haraoui B; van Vollenhoven R; Cioffi C; Ecoffet C; Gervitz L; Ionescu L; Peterson L; Fleischmann R
    Lancet; 2016 Dec; 388(10061):2763-2774. PubMed ID: 27863807
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Three-dimensional nail imaging by optical coherence tomography: a novel biomarker of response to therapy for nail disease in psoriasis and psoriatic arthritis.
    Abignano G; Laws P; Del Galdo F; Marzo-Ortega H; McGonagle D
    Clin Exp Dermatol; 2019 Jun; 44(4):462-465. PubMed ID: 30246363
    [No Abstract]   [Full Text] [Related]  

  • 28. Persistence and adherence of biologics in US patients with psoriatic arthritis: analyses from a claims database.
    Oelke KR; Chambenoit O; Majjhoo AQ; Gray S; Higgins K; Hur P
    J Comp Eff Res; 2019 Jun; 8(8):607-621. PubMed ID: 30912454
    [No Abstract]   [Full Text] [Related]  

  • 29. Usefulness of dual-energy computed tomography for the evaluation of early-stage psoriatic arthritis only accompanied by nail psoriasis.
    Asahina A; Fukuda T; Ishiuji Y; Yaginuma A; Yanaba K; Umezawa Y; Nakagawa H
    J Dermatol; 2017 Dec; 44(12):e326-e327. PubMed ID: 28836684
    [No Abstract]   [Full Text] [Related]  

  • 30. Polyethylene glycol: an underrecognized compound in certolizumab pegol and Movicol that may cause anaphylaxis.
    McCabe E; Tormey V; Doran JP
    Rheumatology (Oxford); 2020 Apr; 59(4):908-910. PubMed ID: 31598712
    [No Abstract]   [Full Text] [Related]  

  • 31. Certolizumab pegol in pregnant and breastfeeding psoriatic patients.
    Lambiase S; Pensa C; Shumak RG; Bianchi L; Dattola A
    Ital J Dermatol Venerol; 2022 Aug; 157(4):383-384. PubMed ID: 35274878
    [No Abstract]   [Full Text] [Related]  

  • 32. Update on TNF Inhibitors.
    Kerdel FA
    Semin Cutan Med Surg; 2016 Jun; 35(4 Suppl 4):S67-70. PubMed ID: 27526035
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical improvement in psoriatic nail disease and psoriatic arthritis with tildrakizumab treatment.
    Ismail FF; May J; Moi J; Sinclair R
    Dermatol Ther; 2020 Mar; 33(2):e13216. PubMed ID: 31899569
    [No Abstract]   [Full Text] [Related]  

  • 34. Nail lesions in psoriatic arthritis: recovery with sulfasalazine treatment.
    Gerster JC; Hohl D
    Ann Rheum Dis; 2002 Mar; 61(3):277. PubMed ID: 11830442
    [No Abstract]   [Full Text] [Related]  

  • 35. Safety and Efficacy of Methotrexate for Chinese Adults With Psoriasis With and Without Psoriatic Arthritis.
    Yan K; Zhang Y; Han L; Huang Q; Zhang Z; Fang X; Zheng Z; Yawalkar N; Chang Y; Zhang Q; Jin L; Qian D; Li X; Wu M; Xu Q; Zhang X; Xu J
    JAMA Dermatol; 2019 Mar; 155(3):327-334. PubMed ID: 30698628
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of risankizumab on nail psoriasis in patients with active psoriatic arthritis: results from KEEPsAKE 1.
    Kristensen LE; Soliman AM; Papp K; Merola JF; Barcomb L; Wang Z; Eldred A; Behrens F
    J Eur Acad Dermatol Venereol; 2022 May; 36(5):e389-e392. PubMed ID: 35032356
    [No Abstract]   [Full Text] [Related]  

  • 37. Hazards of low dose methotrexate.
    Conaghan PG; Quinn DI; Brooks PM; Day RO
    Aust N Z J Med; 1995 Dec; 25(6):670-3. PubMed ID: 8770329
    [No Abstract]   [Full Text] [Related]  

  • 38. Psoriasiform skin eruption in a patient receiving certolizumab-pegol for ankylosing spondylitis: Report of a case and review of the literature.
    Babuna Kobaner G; Polat Ekinci A; Yilmaz Z; Copur S
    Dermatol Ther; 2018 Sep; 31(5):e12693. PubMed ID: 30225952
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Psoriatic onycho-pachydermo-periostitis].
    Miehle W
    Z Rheumatol; 2002 Oct; 61(5):597. PubMed ID: 12399888
    [No Abstract]   [Full Text] [Related]  

  • 40. Certolizumab pegol (Cimzia) and ustekinumab (Stelara) for psoriatic arthritis.
    Med Lett Drugs Ther; 2014 Feb; 56(1435):10-2. PubMed ID: 24662976
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.